Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793843 | 0.86 | CCNA2 (0.39) | CCNA2CDK2CCNA1KDM4EPOLB | |
| SCHEMBL6787887 | 0.78 | MAPT (0.47) | KDM4EPOLB | |
| SCHEMBL6794445 | 0.76 | CCNA2 (0.55) | CCNA2CDK2CCNA1POLBESR1 | |
| SCHEMBL2367630 | 0.67 | POLB (0.56) | KDM4EPOLBESR1ESR2THRA | |
| SCHEMBL30081125 | 0.67 | POLB (0.56) | KDM4EPOLBESR1ESR2THRA | |
| SCHEMBL6790788 | 0.66 | CCNA2 (0.54) | CCNA2CDK2CCNA1KDM4EPOLB | |
| SCHEMBL2172066 | 0.66 | CCNA2 (0.54) | CCNA2CDK2CCNA1KDM4EHSP90AA1 | |
| SCHEMBL1559614 | 0.65 | CCNA2 (0.52) | CCNA2CDK2CCNA1PDPK1 | |
| Hydrochloric Acid SCHEMBL1560040 | 0.64 | CCNA2 (0.51) | CCNA2CDK2CCNA1PDPK1 | |
| SCHEMBL4670538 | 0.64 | POLB (0.34) | KDM4EPOLBESR1ESR2THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CCNA2 270/4885CDK2 29/4885CCNA1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.